<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00972686</url>
  </required_header>
  <id_info>
    <org_study_id>112826</org_study_id>
    <nct_id>NCT00972686</nct_id>
  </id_info>
  <brief_title>Dose-Escalation Study of GSK2126458</brief_title>
  <acronym>FTIH</acronym>
  <official_title>A Phase I Open-Label, Dose-Escalation Study of the Phosphoinositide 3-Kinase Inhibitor GSK2126458 in Subjects With Solid Tumors or Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      P3K112826 is a Phase I, first-time-in-human dose escalation study in subjects with refractory
      malignancy. The primary objective of this study is to determine the recommended Phase II dose
      of GSK2126458 based on safety and tolerability, pharmacokinetics, pharmacodynamics and
      preliminary evidence of clinical activity. Secondary objectives are to characterize the
      pharmacokinetics of GSK2126458; and to explore relationships between GSK2126458
      pharmacokinetics, pharmacodynamics, response prediction biomarkers and clinical endpoints.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a Phase I, first-time-in-human dose escalation study in subjects with
      refractory solid tumors or lymphoma. The primary objective of this study is to determine the
      recommended Phase II dose of GSK2126458 based on safety and tolerability, pharmacokinetics,
      pharmacodynamics and preliminary evidence of clinical activity. Secondary objectives are to
      characterize the pharmacokinetics of GSK2126458; and to explore relationships between
      GSK2126458 pharmacokinetics, pharmacodynamics, response prediction biomarkers and clinical
      endpoints.

      Subjects with solid tumors or lymphoma will initially receive oral GSK2126458 daily for 28
      consecutive days in each 28 day cycle. Subjects may be dosed once or twice a day or may be
      dosed on an intermittent schedule depending on the safety, pharmacokinetic and
      pharmacodynamic results that become available as the study progresses. The starting dose will
      be 0.1 mg once a day. Expansion of some cohorts will be conducted to test tumor
      pharmacodynamics, further explore the toxicity profile and to look for preliminary evidence
      of activity in subjects with tumors with PIK3CA mutations. The recommended Phase II dose will
      be the lowest dose explored (at or below MTD) that maintains biologic activity with an
      acceptable tolerability profile.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 31, 2009</start_date>
  <completion_date type="Actual">March 31, 2015</completion_date>
  <primary_completion_date type="Actual">December 12, 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events (AEs) and changes in laboratory values and vital signs. Pharmacokinetic parameter values for GSK2126458, Change from baseline in protein markers in tumor and/or blood. Blood glucose and insulin levels. Tumor response, RECIST defined</measure>
    <time_frame>Subjects continue on study until disease progression or consent withdrawal</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Metabolic profile in plasma at the maximum tolerated dose</measure>
    <time_frame>Subjects continue on study until disease progression or consent withdrawal</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">79</enrollment>
  <condition>Solid Tumours</condition>
  <arm_group>
    <arm_group_label>GSK2126458</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GSK2126458 will be dosed continuously (every day) for the duration a 28 day cycle. The 28 day cycles will continue until the subjects withdraw from the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK2126458</intervention_name>
    <description>GSK2126458 is an experimental treatment for patients with cancer.</description>
    <arm_group_label>GSK2126458</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically- or cytologically- confirmed diagnosis of solid tumor malignancy, or
             lymphoma

          -  Performance Status score of 0 or 1 according to the Eastern Cooperative Oncology Group
             (ECOG) scale.

          -  Female or male that is willing to take measures to avoid pregnancy in self or a
             partner, including abstinence, or double barrier method.

          -  Adequate organ system function

        Exclusion Criteria:

          -  Use of an investigational anti-cancer medication within 28 days or 5 half-lives
             preceding the first dose of GSK2126458.

          -  Chemotherapy within the last 3 weeks (6 weeks for prior nitrosourea or mitomycin C

          -  Any major surgery, radiotherapy, or immunotherapy within the last 4 weeks.

          -  Prior use of any PI3K inhibitor.

          -  Current use of a prohibited medication or requires any of these medications during
             treatment with GSK2126458.

          -  Presence of an active gastrointestinal disease or other condition known to interfere
             significantly with the absorption, distribution, metabolism, or excretion of drugs.

          -  Unresolved toxicity greater than Grade 1 from previous anti-cancer therapy except
             alopecia.

          -  QTc interval ≥ 480 msecs.

          -  History of acute coronary syndromes; Class II, III, or IV heart failure; stroke or
             subarachnoid hemorrhage.

          -  Systolic blood pressure (SBP) of ≥140 mmHg or diastolic blood pressure (DBP) of ≥
             90mmHg.

          -  Previously diagnosed Type 1 diabetes mellitus. Subjects with Type 2 diabetes are
             prohibited in the dose escalation part of the study.

          -  Symptomatic or untreated leptomeningeal or brain metastases.

          -  Primary malignancy of the central nervous system.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599-7600</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112-5550</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.gsk-clinicalstudyregister.com/study/112826?search=study&amp;b'search_terms=112826'#rs</url>
    <description>Results for study 112826 can be found on the GSK Clinical Study Register.</description>
  </link>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 3, 2009</study_first_submitted>
  <study_first_submitted_qc>September 4, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2009</study_first_posted>
  <last_update_submitted>May 5, 2017</last_update_submitted>
  <last_update_submitted_qc>May 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>solid tumors</keyword>
  <keyword>lymphoma</keyword>
  <keyword>Phosphoinositide 3-kinase inhibitor</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>112826</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>112826</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>112826</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>112826</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>112826</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>112826</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>112826</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

